Form 4: Twist Bioscience CAO Awarded Performance Stock Units

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, was awarded 5,633 shares of common stock through performance stock units.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), acquired 5,633 shares of common stock.
• The acquisition occurred on October 28, 2025, and represents Performance Stock Units (PSUs) for which target criteria were determined to have been met.
• The shares were acquired at a price of $0, indicating an equity award rather than a purchase.
• Following this transaction, Robert F. Werner beneficially owns 52,046 shares of Twist Bioscience common stock.
• 60% of these PSUs remain subject to time-based vesting and will vest on October 1, 2026, contingent upon continued service or acceleration as per the award agreement.

Sentiment

Score: 6

Explanation: The filing indicates a routine executive equity award based on met performance criteria, which is generally a neutral to slightly positive event as it aligns executive incentives with company performance and increases insider ownership.

Positives

• The award of Performance Stock Units indicates that the target criteria set for these units were successfully met, reflecting positive performance by the company or the executive.
• The transaction increases insider ownership, aligning management's interests more closely with those of shareholders.

Risks

• 60% of the awarded PSUs are subject to time-based vesting until October 1, 2026, and are contingent on continued service, meaning the full award is not immediately realized.
• Potential future dilution for existing shareholders when the remaining PSUs fully vest and convert to common stock.

Future Outlook

60% of the awarded Performance Stock Units are subject to future time-based vesting on October 1, 2026, contingent on the Chief Accounting Officer's continued service to the company.

Management Comments

• Management's compensation structure includes performance-based equity awards designed to incentivize the achievement of specific corporate targets.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across publicly traded companies. It reflects the standard practice of executive compensation packages that often include performance-based equity awards to align executive incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it aligns executive interests with shareholder value. However, the future vesting of the remaining PSUs could lead to minor dilution.
• Employees: Reflects the company's executive compensation practices, which often include performance-based incentives.

Next Steps

• The remaining 60% of the awarded PSUs are scheduled to vest on October 1, 2026, subject to continued service.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Performance Stock Units, PSUs, Equity Award, Beneficial Ownership, Chief Accounting Officer, Executive Compensation